STANDARD OF CARE TEMOZOLOMIDE CHEMOTHERAPY ± TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. FINAL RESULTS OF THE PHASE III EF-14 CLINICAL TRIAL

被引：0
|
作者：
Stupp, R. [1 ,2 ]
Ram, Z. [3 ]
机构：
[1] Univ Zurich, Zurich, Switzerland
[2] EF 14 Investigators, Zurich, Switzerland
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS07.9
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Phase 3 TRIDENT trial: Radiation and temozolomide plus /- Tumor Treating Fields in newly diagnosed glioblastoma
    Glas, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S72 - S72
  • [42] Updated safety/feasibility study of concurrent tumor treating fields (TTFields) and radiation therapy for newly diagnosed glioblastoma.
    Grossman, Rachel
    Bokstein, Felix
    Blumenthal, Deborah T.
    Limon, Dror
    Ben Harush, Carmit
    Ram, Zvi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
    S. A. Toms
    C. Y. Kim
    G. Nicholas
    Z. Ram
    Journal of Neuro-Oncology, 2019, 141 : 467 - 473
  • [44] Analysis of the EF-14 Phase 3 Trial Reveals That Tumor-Treating Fields Alter Progression Patterns in Glioblastoma
    Jeyapalan, S.
    Toms, S. A.
    Hottinger, A.
    Kleinberg, L. R.
    Pollom, E.
    Soltys, S. G.
    Glas, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E100 - E101
  • [45] APPLICATION OF RTOG-RPA SCORES IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE (TTFIELDS/TMZ) VERSUS TEMOZOLOMIDE (TMZ) ALONE IN NEWLY DIAGNOSED GLIOBLASTOMA
    Choe, Kevin
    Idbaih, Ahmed
    Taillibert, Sophie
    Escuder, Jordi Bruna
    Sroubek, Jan
    Kanner, Andrew
    NEURO-ONCOLOGY, 2017, 19 : 8 - 9
  • [46] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
    Toms, S. A.
    Kim, C. Y.
    Nicholas, G.
    Ram, Z.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 141 (02) : 467 - 473
  • [47] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, Lazaros
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Tzaridis, Theophilos-Dimitrios
    Scheffler, Bjoern
    Pierscianek, Daniela
    Kleinschnitz, Christoph
    Stuschke, Martin
    Sure, Ulrich
    Herrlinger, Ulrich
    Glas, Martin
    NEURO-ONCOLOGY, 2018, 20 : 119 - 120
  • [48] Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
    Lazaridis, L.
    Kebir, S.
    Weller, J.
    Tzaridis, T. -D
    Scheffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Schaefer, N.
    Glas, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S109 - S109
  • [49] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, L.
    Schaefer, N.
    Kebir, S.
    Weller, J.
    Tzaridis, T.
    Schaeffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Glas, M.
    NEURO-ONCOLOGY, 2018, 20 : 230 - 230
  • [50] Perspective on the EF-14 trial and its implications for the role of tumor-treating fields in the management of glioblastoma
    Mohan, Suyash
    Chawla, Sanjeev
    Skolnik, Aaron
    Poptani, Harish
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S272 - S275
12345